Ophthalmic formulations of cetirizine and methods of use
The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
1. A method for the treatment of signs and symptoms of allergic conjunctivitis and/or rhinoconjunctivitis, the method comprising topically administering to an eye of a subject in need thereof a topical ophthalmic formulation comprising cetirizine at a concentration of from 0.05% to 0.5% (w/v) and naphazoline at a concentration of from 0.01% to 0.5% (w/v).
2. The method according to claim 1 wherein the symptoms of allergic conjunctivitis are ocular itching, redness and eyelid swelling, and nasal symptoms.
3. A method for the treatment of signs and symptoms of allergic conjunctivitis, the method comprising topically administering to an eye of a subject in need thereof a topical ophthalmic formulation comprising:
cetirizine at a concentration of from 0.05% to 0.25% (w/v);
naphazoline at a concentration of from 0.01% to 0.2% (w/v); and
hydroxypropylmethyl cellulose or carboxymethyl cellulose at a concentration of from 0.5% to 1% (w/v), wherein:
the formulation has a viscosity of 60-80 cpi, the formulation does not contain cyclodextrin, and the formulation has a pH of from 5.0 to 7.5.
4. The method according to claim 3 wherein the symptoms of allergic conjunctivitis are ocular itching, redness and eyelid swelling, and associated nasal symptoms.
5. A method for the treatment of signs and symptoms of allergic conjunctivitis and/or rhinoconjunctivitis, the method comprising topically administering to an eye of a subject in need thereof a topical ophthalmic formulation comprising cetirizine at a concentration of from 0.05% to 0.25% (w/v) and oxymetazoline at a concentration of from 0.01% to 0.2% (w/v).
6. The method according to claim 5 wherein the symptoms of allergic conjunctivitis are ocular itching, redness and eyelid swelling, and associated nasal symptoms.
7. A method for the treatment of signs and symptoms of allergic conjunctivitis and/or rhinoconjunctivitis, the method comprising topically administering to an eye of a subject in need thereof a topical ophthalmic formulation comprising:
cetirizine at a concentration of from 0.01% to 0.25% (w/v);
oxymethazoline at a concentration of from 0.01% to 0.1% (w/v); and
hydroxypropylmethyl cellulose or carboxymethyl cellulose at a concentration of from 0.5% to 1% (w/v),
wherein the formulation has a viscosity of 60-80 cpi, the formulation does not contain cyclodextrin, and the formulation has a pH of from 5.0 to 7.5.
8. The method according to claim 7 wherein the symptoms of allergic conjunctivitis are ocular itching, redness and eyelid swelling, and nasal symptoms.